BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Florczyk-Soluch U, Polak K, Dulak J. The multifaceted view of heart problem in Duchenne muscular dystrophy. Cell Mol Life Sci 2021;78:5447-68. [PMID: 34091693 DOI: 10.1007/s00018-021-03862-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Polak K, Stępniewski J, Ścieżyńska A, Podgórska A, Dulak J, Florczyk-Soluch U. Generation of human induced pluripotent stem cell lines with HMOX1 promoter polymorphism and CRISPR/Cas9-mediated deletion of exon 50 of DMD gene. Stem Cell Res 2023;66:103004. [PMID: 36565681 DOI: 10.1016/j.scr.2022.103004] [Reference Citation Analysis]
2 Kracht KD, Eichorn NL, Berlau DJ. Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy. Expert Opin Pharmacother 2022. [PMID: 36168943 DOI: 10.1080/14656566.2022.2130246] [Reference Citation Analysis]
3 Du Y, Demillard LJ, Ren J. Sarcoplasmic Reticulum Ca2+ Dysregulation in the Pathophysiology of Inherited Arrhythmia: An Update. Biochemical Pharmacology 2022;200:115059. [DOI: 10.1016/j.bcp.2022.115059] [Reference Citation Analysis]
4 Migliore B, Zhou L, Duparc M, Robles V, Rehder C, Peay H, Kucera K. Evaluation of the GSP Creatine Kinase-MM Assay and Assessment of CK-MM Stability in Newborn, Patient, and Contrived Dried Blood Spots for Newborn Screening for Duchenne Muscular Dystrophy. IJNS 2022;8:12. [DOI: 10.3390/ijns8010012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Jariwala P, Jadhav K, Khetan S. Effectiveness and Safety of Sacubitril/Valsartan for Heart Failure with Reduced Ejection Fraction Secondary to Duchenne Muscular Dystrophy-Associated Cardiomyopathy. J Indian Acad Echocardiogr Cardiovasc Imaging 2022;0:0. [DOI: 10.4103/jiae.jiae_17_22] [Reference Citation Analysis]
6 Kaziród K, Myszka M, Dulak J, Łoboda A. Hydrogen sulfide as a therapeutic option for the treatment of Duchenne muscular dystrophy and other muscle-related diseases. Cell Mol Life Sci 2022;79:608. [PMID: 36441348 DOI: 10.1007/s00018-022-04636-0] [Reference Citation Analysis]